OpenAI acquired Orchestra Bio, a San Francisco startup whose AI agents track drug-development programs, and will fold its team and platform into Rosalind, the company’s life-sciences suite. Financial terms were not disclosed. Orchestra’s software maps how problems such as a failed manufacturing batch affect schedules and related activities, compiles relevant information and compares response options, while scientists and program leaders retain final decision-making authority. The acquisition extends Rosalind beyond scientific analysis and experiment planning into the operational work required to move potential medicines through development. OpenAI says developing a medicine can take up to 15 years and cost more than $2.6 billion, while fewer than 10% of candidates entering human testing reach pharmacy shelves. The transaction follows Anthropic’s roughly $400 million acquisition of Coefficient Bio in April, underscoring competition among AI labs to provide tools across drug-research and development workflows.